Efficacy and safety of a fixed low-dose perindopril/indapamide combination in essential hypertension. A randomised controlled study

Clinical and Experimental Hypertension

Volumn 22, Issue 1, 2000, Pages 23-32

  Mallion, Jean Michel ^a,d   Chastang, Claude ^b   Unger, Philippe ^c  

^a HÔPITAL MICHALLON   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c EURAXI ^*  (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

ACE inhibitor; Beta blocker; Diuretic; Fixed low dose combination; Hypertension

Indexed keywords

ATENOLOL; INDAPAMIDE; PERINDOPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; PERINDOPRIL; SAFETY; TREATMENT OUTCOME;

EID: 0033953123     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-100100059     Document Type: Article

References (31)

1. Chalmers J, Zanchetti A. The 1996 report of a World Health Organisation expert committee on hypertension control. J. Hypertens. 1996;14:929-33.
2. Collins R, Peto R, Mac-Mahon S, Hebert P, Fiebach N, Eberlein KA, Godwin J, Qizilbash N, Taylor J, Hennekens C. Blood pressure, stroke, and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-38.
3. Hansson L, Zanchetti A, Carruthers G, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn K, Wedel H, Westerling S for the HOT Study Group. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351: 1755-62.
4. Mulrow PJ. Detection and control of hypertension in the population - The United States Experience. Am J Hypertens. 1998;11:744-46.
5. Chockalingam A, Fodor JG. Treatment of raised blood pressure in the population -The Canadian experience. Am J Hypertens. 1998;11:747-49.
6. Faulhaber HD, Luft FC. Treatment of high blood pressure in Germany. Am J Hypertens. 1998;11:750-53.
7. Chamontin B, Poggi L, Lang T, Ménard J, Chevalier H, Gallois H, Crémier O. Prevalence, treatment and control of hypertension in the French population. Data from a survey on high blood pressure in General practice, 1994. Am J Hypertens. 1998;11:759-62.
8. Pardell H, Tresseras R, Armario P, Hernandez R. Actions implemented to improve hypertension control in Spain. Am J Hypertens. 1998;11:763-65.
9. Colhoun M, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens. 1998; 16:747-52.
10. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, Swales J. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993;306:983-87.
11. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157(21):2413-46.
12. Wadworth A, Murdoch D, Brodgen RN. Atenolol - a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 1991;42:468-510.
13. Castaigne A, Chalmers J, Morgan T, Chastang C, Feldmann L, Guez D. Efficacy and safety of an oral fixed low dose perindopril 2mg/ indapamide 0.625 mg combination: a randomised, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension. Clin Exp Hypertens. In Press
14. Forette B, Feldmann L, Laurandin I, Lachaud-Pettiti, Brault Y, Guez D. Safety and efficacy of a fixed combination of perindopril and /indapamide in 50 elderly patients. Am J Hypertens. 1997;10(4 part 2):111A.
15. Myers M, Leenen F, Brault Y, Rivaille F, Guez D, Safar M. Determination de la dose optimale de Perindopril associé à Indapamide dans le traitement de l'hypertension artérielle essentielle. Arch Mal CŒur Vaiss. 1996;89HS:34.
16. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;657-80.
17. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Arch Intern Med. 1996;156:1969-78.
18. Menard J. Critical assessment of combination therapy development. Blood Press. 1993;2(Supp 1):5-9.
19. Sever PS. Blood pressure control for the hypertensive patient. What can we do better Am J Hypertens. 1997;10:128S-3.
20. Brunner H, Ménard J, Waeber B, Burnier M, Biollaz J, Nussberger J, Bellet M. Treating the individual hypertensive patient: considerations on dose sequential monotherapy an drug combinations. J. Hypertens. 1990, 8:3-11.
21. Waeber B, Brunner H. Combination antihypertensive therapy: Does it have a role in rationale therapy? Am J Hypertens. 1997;10:131S-137S.
22. Committee for Proprietary Medicinal Products. Note for guidance: clinical investigation of medicinal products in the treatment of hypertension. Brussels, European Commission, May 1997.
23. Menard J, Chatellier G. Limiting factors in the control of BP: Why is there a gap between theory and practice. J Hum Hypertens. 1995;9(supp 2):S19-S23.
24. Opie LH. Principles of Combination Therapy for Hypertension. In Opie LH, Messerli FH editors: Combination Drug Therapy for Hypertension. New York: Authors' Publishing House - Lippincott-Raven Publishers. 1997, pp. 1-10.
25. Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med. 1994;154:1430-31.
26. Waeber B, Brunner H. Main objectives and new aspects of combination treatment of hypertension. J Hypertens. 1995, 13(suppl 2):S15-S19.
27. Psaty B, Smith N, Siscovick D, Koepsell T, Weiss N, Heckbert S, Lemaitre R, Wagner E, Furberg C. Health Outcomes associated with antihypertensive therapies used as first line agents - A systematic review and Meta-analysis. JAMA. 1997;277: 7395.
28. Westlake W. Bioequivalence testing. A need to rethink. Biometrics. 1981;37:580-94.
29. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Welleck S on behalf of the Hane Trial Research Group. Randomized, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the Hane study. BMJ. 1997;315:154-9.
30. Os I, Hotnes T, Dollerup J, Mogensen CE. Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild to moderate hypertension. Am J Hypertens. 1997;10:899-904.
31. Messerli F H, Grossman E, Goldbourt U. Are β-blockers efficacious as first line therapy for hypertension in the elderly - A systematic review. JAMA. 1998;279:1903-07.